Table 3 Clinico-pathological data and distribution of scores in the entire cohort of patients with pre- and post-CRT available specimens
E-cadherin | Nuclear β-catenin | ||||||||
|---|---|---|---|---|---|---|---|---|---|
Factors | N (%) 69 (100) | Absent | Low | Mode-rate | High | Absent | Low | Mode-rate | High |
Sex | |||||||||
M | 50 (73%) | 1 (2%) | 1 (2%) | 7 (14%) | 41 (82%) | 24 (48%) | 14 (28%) | 3 (16%) | 3 (6%) |
F | 19 (27%) | 1 (5%) | 0 (0%) | 4 (21%) | 14 (74%) | 9 (47%) | 7 (37%) | 9 (18%) | 0 (0%) |
Age | |||||||||
</= 50 | 8 (12%) | 0 (0%) | 0 (0%) | 2 (25%) | 6 (75%) | 4 (50%) | 2 (25%) | 1 (12%) | 1 (13%) |
>50 | 61 (88%) | 2 (3%) | 1 (2%) | 9 (15%) | 13 (21%) | 29 (47%) | 19 (31%) | 11 (18%) | 2 (3%) |
Anal margin | |||||||||
<= 5 cm | 34 (49%) | 1 (3%) | 1 (3%) | 5 (15%) | 27 (79%) | 18 (53%) | 8 (23%) | 5 (15%) | 3 (9%) |
>5 cm | 35 (51%) | 1 (3%) | 0 (0%) | 6 (17%) | 28 (80%) | 15 (43%) | 13 (37%) | 7 (20%) | 0 (0%) |
T stage | |||||||||
T2-3 | 54 (79%) | 2 (4%) | 1 (2%) | 8 (15%) | 33 (80%) | 24 (44%) | 17 (32%) | 10 (18%) | 3 (6%) |
T4 | 15 (22%) | 0 (0%) | 0 (0%) | 3 (20%) | 12 (80%) | 9 (60%) | 4 (27%) | 2 (13%) | 0 (0%) |
N stage | |||||||||
N- | 37 (54%) | 0 (0%) | 1 (3%) | 5 (13%) | 31 (84%) | 18 (49%) | 9 (24%) | 8 (22%) | 2 (5%) |
N+ | 32 (46%) | 2 (6%) | 0 (0%) | 6 (20%) | 24 (75%) | 15 (47%) | 12 (37%) | 4 (13%) | 1 (3%) |
TGR * | |||||||||
TGR 2 | 20 (29%) | 1 (5%) | 0 (0%) | 2 (10%) | 17 (85%) | 7 (35%) | 7 (35%) | 5 (25%) | 1 (5%) |
TGR 3 | 20 (29%) | 1 (5%) | 1 (5%) | 1 (5%) | 17 (85%) | 11 (55%) | 5 (25%) | 3 (15%) | 1 (5%) |
TGR 4 | 24 (26%) | 0 (0%) | 0 (0%) | 6 (25%) | 18 (75%) | 13 (54%) | 7 (29%) | 3 (13%) | 1 (4%) |
TGR 5 | 5 (7%) | 0 (0%) | 0 (0%) | 2 (40%) | 3 (60%) | 2 (40%) | 2 (40%) | 1 (20%) | 0 (0%) |
pN †† | |||||||||
pN- | 46 (67%) | 0 (0%) | 1 (4%) | 2 (9%) | 20 (87%) | 22 (48%) | 14 (30%) | 8 (17%) | 2 (4%) |
pN+ | 23 (33%) | 2 (4%) | 0 (0%) | 9 (20%) | 35 (66%) | 11 (49%) | 7 (30%) | 4 (17 %) | 1 (4%) |